|
Researchspace >
General science, engineering & technology >
General science, engineering & technology >
General science, engineering & technology >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10204/4542
|
| Title: | Future of aptamers in medicine |
| Authors: | Khati, M |
| Keywords: | Aptamers Oligonucleotide ligands Clinical prospects Peptides Monoclonal antibodies |
| Issue Date: | Jun-2010 |
| Publisher: | BMJ Publishing Group |
| Citation: | Khati, M. 2010. Future of aptamers in medicine. Journal of Clinical Pathology, Vol.63(6), pp 480-487 |
| Series/Report no.: | Journal Article |
| Abstract: | Aptamers, simply described as chemical antibodies, are synthetic oligonucleotide ligands or peptides that can be isolated in vitro against diverse targets including toxins, bacterial and viral proteins, virus infected cells, cancer cells and whole pathogenic microorganisms. Aptamers assume a defined three-dimensional structure and generally bind functional sites on their respective targets. They possess the molecular recognition properties of monoclonal antibodies in terms of their high affinity and specificity. The applications of aptamers range from diagnostics and biosensing, target validation, targeted drug delivery, therapeutics, templates for rational drug design to biochemical screening of small molecule leads compounds. The review describes recent progress made in the application of biomedically relevant aptamers and relate them to their future clinical prospects. |
| Description: | Copyright: 2010 BMJ Publishing Group |
| URI: | jcp.bmj.com http://hdl.handle.net/10204/4542 |
| Appears in Collections: | Aptamer technology General science, engineering & technology
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|